Brazil Senate discusses pathways for advancement of clinical research

The Brazilian Senate's Social Affairs Committee (CAS) held a hearing on March 18 to debate the progress and challenges of clinical research of medicines in Brazil. The event was attended by representatives of the government's regulatory agencies involved in human clinical research as well as and members of the scientific communities in the country, says Juliane Carvalho writing on Brazil Pharma News.

One of the issues most frequently mentioned by the representatives of the scientific reps was the need to accelerate the analysis of clinical research for the country to be able to participate in a larger number of studies. Nowadays, human clinical research takes place simultaneously in several countries.

According to ANVISA (Brazil's National Health Surveillance Agency) Chief Commissioner Dirceu Barbano, clinical research is fundamental to people's access to new drugs and the development of a national industry for drugs but it is necessary to adopt all necessary precautions to ensure that the rights and safety of volunteers in research are guaranteed.